JYNNEOS® is now available as the only FDA-approved mpox vaccine in the U.S

Bavarian Nordic A/S announced the commercial availability of JYNNEOS®, the only FDA-approved mpox vaccine in the U.S. Since 2022, over 32,000 mpox cases have been reported in the U.S. with 60% of eligible individuals unvaccinated. JYNNEOS is now recommended for routine use in at-risk individuals 18 years and older. The vaccine is available nationwide through healthcare providers, aiming to increase awareness and availability.